BACKGROUND

ChanTest's primary focus is on ion channels that may be either deliberate therapeutic targets or unintended targets resulting in unwanted side effects. In particular, drug-induced blockade of cardiac potassium channels may be lead to impaired delayed repolarization, QT prolongation and torsades de pointes. ChanTest has pioneered the hERG potassium channel assay as a preclinical predictor of delayed repolarization. ChanTest has tested more than 10,000 compounds,, has been audited for GLP Compliance by over 100 companies, and the FDA, and has assisted more than 100 pharmaceutical companies in achieving their drug safety and discovery goals.